Provided by Tiger Fintech (Singapore) Pte. Ltd.

AMGEN-T

1,850.000
0.000
Volume:- -
Turnover:- -
Market Cap:1.13T
PE:19.54
High:1,850.000
Open:1,850.000
Low:1,850.000
Close:1,850.000
52wk High:1,850.000
52wk Low:1,850.000
Shares:609.94M
HK Float Shares:609.94M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):94.676
ROE:133.80%
ROA:7.86%
PB:18.96
PE(LYR):19.54
PS:5.41

Loading ...

Company Profile

Company Name:
AMGEN-T
Exchange:
SEHK
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.